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ABSTRACT 
To determine the incidence of transient congenital hypothyroidism 
due to TSH receptor-blocking antibodies, we screened dried blood 
specimens obtained from 788 neonates identified as having possible 
congenital hypothyroidism (from a total population of 1,614,166 ba- 
bies) and 121 controls. A RRA was used. The potency ofblood spot TSH 
binding inhibitory activity was compared with the severity of con- 
genital hypothyroidism to assess the possible etiological relationship. 
Maternal serum was studied to confirm the presence of blocking 
antibodies by both RRA and bioassay. 
Blood spots obtained from 9 infants contained potent TSH receptor- 
blocking activity. Samples from 2 additional babies, studied because 
of clinical suspicion of the disease, were also positive. Long term 
outcome was known in 8 of the 11 babies, and all had transient 
disease. Neonates with TSH receptor-blocking. activity greater than 
132 U/L had a significantly lower T4 level (P <0.05) andhigher TSH 
(P < 0.005) than those in whom TSH bindine-inhibitorv activitv was 
less than 132 U/L. All 9 mothers had autoikmune thiroid disease, 
and 3 had more than 1 affected child. Potent blocking activity was 
present in 7 maternal serum samples as long as 7 yr after the births 
of their affected babies. 
We conclude that measurement of TSH binding-inhibitory activity 
in dried neonatal blood specimens is a simple and effective method to 
predict the occurrence of transient congenital hypothyroidism. The 
incidence of this disorder in North America is 1 in 180,000 normal 
infants, or approximately 2% of babies with congenital hypothyroid- 
ism. (J Clin Endocrinol Metab 81: 1147-1151, 1996) 
C ONGENITAL hypothyroidism occurs in 1 in 4000 new- born babies and is one of the most frequent prevent- 
able causes of mental retardation (1). Although the majority 
of affected infants have a defect in thyroid gland develop- 
ment or thyroid hormone synthesis and will, therefore, re- 
quire lifelong thyroid hormone replacement (2), in approx- 
imately 10% of babies detected by newborn screening, the 
abnormality in thyroid function will be transient (1). Recent 
interest has focused on the possible etiological role in some 
of these transient cases of maternal TSH receptor-blocking 
antibodies. Although difficult to distinguish at birth from 
those with the more common thyroid gland dysgenesis, af- 
fected infants differ from the latter in a number of important 
ways (3-5). They do not require lifelong therapy, results of 
thyroid imaging may be misleading in them, and there is a 
high recurrence rate in subsequent offspring due to the ten- 
dency of these antibodies to persist for many years in the 
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maternal circulation (>5). Furthermore, others have suggested 
recently that the intellectual outcome of babies with maternal 
blocking antibody-induced congenital hypothyroidism may be 
less favorable than that of babies with a permanent abnormality 
of the thyroid gland, especially if unrecognized maternal hy- 
pothyroidism was present in uhvo (6). 
The incidence of transient congenital hypothyroidism sec- 
ondary to maternal TSH receptor-blocking antibodies is un- 
known, and most information derived about this syndrome 
to date has been obtained from isolated case reports (3-5,7). 
In the present study, we have taken advantage of the recent 
observation that affected babies can be identified by evalu- 
ation of [‘251]TSH binding inhibitory activity in dried neo- 
natal blood specimens obtained for routine screening pur- 
poses (8). We have employed this technique to evaluate the 
incidence of this disorder in more than 1.6 million babies 
born in New York State over a 6-yr period and have analyzed 
the clinical and immunological data in a total of 9 babies so 
discovered as well as in their mothers. Data from 2 additional 
infants in whom the diagnosis was suspected clinically were 
evaluated similarly. We also sought to establish whether an 
etiological relationship was present by relating the potency 
of the blocking antibodies to the severity of congenital 
hypothyroidism. 
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Subjects and Methods 
Study population 
A total of 899 dried blood specimens were obtained from 788 newborn 
infants in whom the screening levels of T, were less than the tenth 
percentile for the assay and whose TSH concentrations were equal to or 
greater than 40 U/L; infants who had an initial diagnosis of congenital 
hypothyroidism reported to the New York State Newborn Screening 
Program were also studied. These infants were selected from among 
1,614,166 babies screened for congenital hypothyroidism in New York 
State over the 6-yr period from 1984-1989. Blood spots from 121 normal 
or T,-binding globulin-deficient babies screened during the same period 
served as control specimens. The results with 465 test specimens and 88 
controls obtained between 1987-1988 were reported in a previous pilot 
study (8). Dried blood specimens from an additional 2 babies were 
studied because of suspicion of the disease and are included in the 
clinical analysis. Blood spots were stored desiccated at -20 C before use 
and were studied without knowledge of the diagnosis. The study was 
approved by the University of Massachusetts Medical Center Commit- 
tee for the Protection of Human Subjects in Research. 
Methods 
Dried blood specimens were eluted overnight in either 50% Coon’s 
F-12 medium or 10 mmol/L Tris-HCl, pH 7.5, containing 50 mmol/L 
NaCl; both solutions gave equivalent results. The presence of TSH re- 
ce tor-blocking activity was estimated in duplicate by evaluation of 
&]TSH binding inhibition to solubilized porcine receptor by the 
method of Southgate et al. (9) using either materials we prepared (8) (part 
1) or a commercial kit (Kalibre, Kronus, Dana Point, CA; part 2). In part 
1, blocking activity was expressed as the percent TSH binding inhibition 
according to the formula (1 - [‘2511bovine TSH binding in the presence 
of test IgG/l - [“51]bovine TSH binding in the presence of normal IgG) 
x 100. In part 2, results were expressed as the TSH receptor antibody 
(TRAb) concentration in units per L by comparison with a standard 
curve. A value greater than 2 SD above the mean for normal infants was 
considered abnormal. We repeated the measurement if the level of 
blocking activity was greater than 1.5 SD above the normal mean. Only 
spots with significant blocking activity in at least two assays were 
considered positive. After a positive spot was confirmed, clinical infor- 
mation was sought and, if not performed previously, a blood sample was 
obtained from the mother for measurement of blocking antibodies. 
To ascertain whether the maternal serum blocked the bioactivity of 
TSH as well as its binding, we measured the inhibition of TSH-induced 
stimulation of adenyl cyclase using recombinant human TSH receptor 
that had been stably transfected into Chinese hamster ovary cells; the 
latter were a generous gift from Dr. Leonard Kohn, NIH. Cells were 
grown overnight to confluence in Costar 24-well plates containing 
Coon’s Modified F-12 buffer and 0.2% FBS. Before assay, cells were 
washed twice with hypotonic HBSS containing 0.5 mmol/L 3-isobutyl- 
L-methyl-xanthine (10) and incubated for 1 h at 37 C in the same buffer 
plus 100 mU/L recombinant human TSH (Genzyme Corp., Cambridge, 
MA). CAMP released into the medium was measured by RIA (Incstar 
Corp., Stillwater, MN). 
Thyroid peroxidase (TPO) antibodies were measured by RIA (Kro- 
nus). Values greater than 1 U/L were considered abnormal. In one case 
in which data obtained previously was used for the analysis, the assay 
in current clinical use was employed. 
Statistics 
The significance of the difference between groups was evaluated by 
Student’s t test. P < 0.05 was considered significant. 
Results 
Dried blood specimens from a total of 11 neonates were 
found to contain significant TSH binding inhibitory activity. 
Nine of these were obtained from the screening portion of the 
study; 2 additional babies were identified because of clinical 
suspicion of the disorder. Three of the former cases have been 
reported previously (8). In all instances, blocking activity was 
extremely potent, being at least 3 SD above the mean for 
normal newborns. In 7 of the cases, the level was more than 
4 SD, and in 3, it was greater than 20 SD. 
The available clinical data for the 11 infants are presented in 
Table 1. All 8 babies in whom follow-up information was avail- 
able had transient disease. Those babies with the most potent 
TSH binding inhibitory activity had the most severe hypothy- 
roidism, as determined by comparison with results of thyroid 
function tests performed in the same spots at the time of new- 
born thyroid screening. Furthermore, in this group of babies, 
the antibodies were sufficiently potent to block TSH-induced 
uptake of radioactive iodine on thyroid scan, leading to the 
misdiagnosis of thyroid agenesis. In part 2, a sufficient number 
of babies was studied to permit statistical analysis. As demon- 
strated in Fig. 1, the 3 infants with the highest TSH binding 
inhibitory activity (>132 U/L) had a significantly lower mean 
T, concentration on neonatal screening (mean 2 SD, 47 % 21 vs. 
93 + 39 nmol/L; P < 0.05) and a significantly higher TSH level 
(>200 us. 85 2 48 mu/L; P < 0.05) than those with TSH binding 
inhibitory activity less than 132 U/L. 
TABLE 1. Clinical and laboratory data of 11 infants with transient congenital hypothyroidism due to maternal TSH receptor-blocking 
antibodies 
Snot No. Spot TBI/“lXAb (%, U/L)” Spot T, hmdiL) Spot TSH (mu/L) Clinical course Thyroid scan 
Part 1 
157 
394 
320 
Part 2 
747 
574 
Al88 
All8 
Al35 
784 
1002 
Al86 
Normal < 
61 a4 
55 116 
51 116 
>132 39 
>132 71 
>132 <31 
57 <31 
61 84 
87 103 
58 84 
72 148 
1231 ~37 1 .03-309 
>200 
>200 
75 
>200 
>200 
>200 
150 
120 
120 
75 
45 
<20 
Unknown 
Transient 
Transient 
Transient 
Transient 
Transient 
Unknown 
Transient 
Transient 
Transient 
Still on Rx. 
No uptake 
Normal 
Not done 
No uptake 
No uptake 
No uptake 
Not done 
Normal 
Normal 
Not done 
Not done 
a In part 1, blocking activity was calculated according to the formula (1 - [‘2511-bTSH binding in the presence of test IgG/l - [12”11-bTSH 
binding in the presence of normal IgG) X 100 and expressed as percent TSH binding inhibition, TBI. In part 2, the TSH receptor antibody (TRAb) 
concentration was expressed as units per L by comparison with a standard curve, according to the instructions of the manufacturer. 
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FIG. 1. Relationship between TSH re- 
ceptor-blocking antibodies and neona- 
tal thyroid function. Infants with the 
most potent blocking activity (TRAb, 
Clinical information in the mothers is presented in Table 2. 
The 11 babies were born to 9 mothers, all of whom had been 
diagnosed as having hypothyroidism and were being treated 
with thyroid hormone. Three of the mothers had been treated 
initially for Graves’ disease. None of the 4 mothers examined 
had a palpable goiter. Two mothers had more than 1 affected 
child, and 1 has had, in turn, a normal infant, one with hyper- 
thyroidism, and one with hypothyroidism (11). The presence of 
TRAb was confirmed around the time of delivery in 3 of the 9 
mothers. Blood was obtained in 5 mothers 2.3-7.6 yr after birth 
(or, in mothers 320 and A188, after the birth of their first affected 
infants). Potent [iz51]TSH binding inhibitory activity persisted 
in all sera at a dilution of 1:40 to 1:160 (Fig. 2). Similarly, all sera 
studied contained potent in vitro blocking activity, as measured 
by inhibition of TSH-induced stimulation of CAMP, which was 
detectable in serum at a dilution of 1:50 (Fig. 2). In comparison, 
the stimulatory effect of most Graves’ IgG cannot be demon- 
strated using unextracted serum in this assay system, but re- 
quires prior IgG purification. 
210 
180 
150 
120 
90 
60 
30 
0 
There was no apparent loss of blocking activity for at least 
6 yr; two positive spots were identified in each of the years 
1984,1985, and 1986, and one in 1989. Furthermore, no sig- 
nificant difference in TSH binding inhibitory activity was 
observed between spots from control babies with T,-binding 
globulin deficiency from 1984 VS. 1989 (13.0 ? 3.6 VS. 14.3 2 
3.9 U/L; P = N’S). 
In contrast to the striking TSH receptor-blocking activity, 
TPO antibody concentrations were variable and, in fact, were 
of only borderline significance in two patients. 
Discussion 
In this study, we screened neonatal blood spots for TSH 
binding inhibitory activity to estimate the incidence of tran- 
sient blocking antibody-induced congenital hypothyroidism 
in North America and elucidate whether the potency of the 
blocking antibodies is related to the degree of neonatal hy- 
pothyroidism. To attempt to identify all such affected infants, 
TABLE 2. Clinical and laboratory data of mothers of infants with transient congenital hypothyroidism 
Spot No. Clinical history Serum TBIPTRAb (%, U/L) Serum TPO Abs 
157 Hypothyroid on Rx. 85.5” 376b 
394 Hypothyroid S/P GD on Rx, MGM hypothyroid 82.8” 17.0” 
320 Hypothyroid on Rx. MGGM, + maternal aunt with GD >132 1.3’ 
747 Hypothyroid on Rx for 9 yr Not done Not done 
574 Hypothyroid S/P GD on Rx 90.0” Not done 
A188 Hypothyroid on Rx for 7 yr, 2nd infant with CH, MGM with GD >132 28.0” 
A118 Hypothyroid on Rx, GM + aunt with “thyroid problem” Not done Not done 
Al35 Hypothyroid S/P Graves; on Rx >132 1.5” 
784 Hypothyroid on Rx for 2 yr >132 5.8’ 
1002 Same as no. 320 
Al86 Same as no. 320 
Normal <15/ <15 
TBI, TSH binding inhibition; TRAb, TSH receptor antibody; Rx, treatment; S/p, status post; GD, Graves’ disease; MGM, maternal grand- 
mother; GM, grandmother; MGGM, maternal great grandmother; CH, congenital hypothyroidism. 
D Performed at Nichols Institute (San Juan Capistrano, CA). 
b Performed elsewhere, details not available (normal, <25). 
c Performed in this laboratory, as described in Materials and Methods (normal, <l U/L). 
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1. Binding Assay 2. Functional Assay’ 
FIG. 2. TSH receptor-blocking activity 
of maternal serum. Maternal serum (0) 
obtained 2.3-7.6 yr after delivery of the 
affected infant still contained potent 
blocking activity whether measured by 
RRA (left) or bioassav (right). See text 
for details. 0, Normal -nonpregnant 
women. 
25 
I I 
I 160 I.80 1:40 I:20 NEAT 
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we studied dried blood specimens obtained not only from 
babies with confirmed congenital hypothyroidism, but from 
any baby whose initial T, was in the lowest 10% for the assay 
or whose TSH was 40 U/L or more. Nine babies from a total 
population of 1,614,166 were found to have TSH receptor 
blocking antibody-induced congenital hypothyroidism, giv- 
ing an incidence of about 1 in 180,000. As the incidence of 
congenital hypothyroidism in North American has been es- 
timated to be 1 in 4,000, this suggests that 1 in 45 infants, or 
approximately 2% of cases of congenital hypothyroidism, are 
caused by maternal TSH receptor-blocking antibodies. 
In all cases, the finding of a blood spot with significant TSH 
binding inhibitory activity correctly identified a baby with 
transient congenital hypothyroidism. Furthermore, potent 
TSH receptor-blocking activity was confirmed in all maternal 
sera studied. In fact, dose-response studies revealed that the 
inhibitory activity in maternal serum, which was evaluated 
as long as 7 yr after the baby’s birth, was sufficiently potent 
that it could be demonstrated at a 1:40 to 1:200 dilution of 
serum in the RRA and at a 1:50 dilution in the bioassay 
employed. Although the underlying immunological mech- 
anisms remain unclear, the persistence of these blocking 
antibodies in some patients for many years explains the 
tendency for a mother to have multiple affected offspring. 
The tendency for others to switch from secreting a prepon- 
derance of stimulatory to blocking antibodies complicated in 
some cases by decreased thyroid gland responsivity is the 
basis for the change from hyperthyroidism to hypothyroid- 
ism (11, 12). Hypothyroidism can also precede hyperthy- 
roidism (13). In rare instances, a more complicated neonatal 
picture can result due to the coexistence of blocking anti- 
bodies and stimulatory ones. In this case, a delayed onset of 
neonatal Graves’ disease occurs because of the progressive 
dilution of the more potent inhibitory effect over time (14). 
In the present study, two mothers had more than one affected 
infant, and one patient has had successively a normal, a 
hyperthyroid, and a hypothyroid baby. For these reasons, 
genetic counselling is of utmost importance to alert mothers 
of the high risk of recurrence and to ensure prompt evalu- 
ation (and treatment) of all subsequent offspring. 
Babies with the most potent TSH binding inhibitory ac- 
0 
. 
: 
10 ‘1 In so duuuon 
0 
NORMAL I'MYXEDEMA 
CONTROB MOTHERS 
tivity had the most profound hypothyroidism, as determined 
by thyroid function testing on the same dried blood speci- 
mens and had the most severe inhibition of radioisotopic 
uptake on thyroid scan. These findings as well as the tran- 
sient course in all babies identified provide strong evidence 
that the maternal blocking antibodies were of etiological 
importance in the hypothyroidism observed. This relation- 
ship between blocking activity and the severity of congenital 
hypothyroidism in the offspring has been reported previ- 
ously in maternal serum (15,16). Maternal sera also inhibited 
recombinant human TSH-induced adenyl cyclase stimula- 
tion of recombinant human TSH receptor, verifying that the 
blocking antibodies inhibited the action of TSH on the human 
receptor in vitro. 
Despite being exposed to potent TSH receptor-blocking 
activity in mtero, these infants did not develop any long term 
abnormality in thyroid function. This is consistent with the 
fact that TSH receptor-blocking antibodies, like other IgG, do 
not cross the placenta until 16 weeks (17) and, therefore, 
could not play a role in early thyroid embryogenesis. 
All mothers, like those identified in previous studies (3-5, 
7) had underlying autoimmune thyroid disease. All were 
receiving thyroid replacement because of hypothyroidism, 
and in three, this had been preceded by a hyperthyroid 
phase. This suggests that only babies born to mothers with 
underlying autoimmune thyroid disease are at risk for the 
development of blocking antibody-induced congenital hy- 
pothyroidism. However, severe hypothyroidism in some 
mothers was not diagnosed until they were postpartum, and 
their babies were found to have congenital hypothyroidism 
due to TSH receptor-blocking antibodies (18). Also, it should 
be emphasized that TPO antibodies, although detectable in 
all mothers, were of no use in predicting the development of 
transient disease in the neonate. 
In summary, we estimate the incidence of TSH receptor- 
blocking antibody-induced congenital hypothyroidism to 
be 1 in 180,000, or about 2% of all cases of congenital 
hypothyroidism. Whether routine screening for the pres- 
ence of maternal TSH receptor-blocking antibodies should 
be performed in all babies with congenital hypothyroid- 
ism and whether mothers or babies should be studied will 
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depend on further information about the prevalence of 
these antibodies in pregnant women, a careful cost anal- 
ysis, and whether decreased intellectual ability occurs in 
some of these infants despite adequate postnatal therapy. 
In the meantime, the diagnosis should be suspected when- 
ever congenital hypothyroidism is diagnosed in the baby 
of a mother with hypothyroidism due to autoimmune 
thyroid disease, particularly if previous offspring have 
had congenital hypothyroidism. Similarly, any baby with 
eutopic thyroid tissue evident on thyroid ultrasound 
should be studied regardless of the thyroid scan result. 
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